How it works, simply
A peptide carries a radioactive component to cells with the matching somatostatin receptor.
What the evidence tells us
This is specialist cancer treatment, not a routine peptide injection or wellness product.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
- Radiation exposure and effects on bone marrow and kidneys require specialist monitoring.
- Secondary blood cancers are a recognized risk in the label.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Targets somatostatin receptors to deliver beta radiation to receptor-positive cells.
Sponsor or developer: Novartis
Studied or labeled topics: Gastroenteropancreatic neuroendocrine tumors, Theranostics
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- DailyMed: LUTATHERA prescribing information ↗ · Regulator · Jan 16, 2026
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (linked label: purpose and selected risks). A wording update is not a new clinical review.